TTBK2 Gene Spinocerebellar Ataxia Type 11 Autosomal Dominant Genetic Test
Welcome to DNA Labs UAE, where we offer the TTBK2 Gene Spinocerebellar Ataxia Type 11 autosomal dominant genetic test. This test is designed to detect and diagnose Spinocerebellar Ataxia Type 11 (SCA11), an autosomal dominant genetic disorder characterized by progressive ataxia and other neurological symptoms.
Test Components and Price
The TTBK2 Gene Spinocerebellar Ataxia Type 11 autosomal dominant genetic test is priced at 4400.0 AED. The test requires a blood or extracted DNA sample, or one drop of blood on an FTA card.
Report Delivery
Once the sample is received, the report will be delivered within 3 to 4 weeks.
Method and Test Type
The TTBK2 Gene Spinocerebellar Ataxia Type 11 autosomal dominant genetic test utilizes Next-generation sequencing (NGS) technology. NGS allows for high-throughput DNA sequencing and the analysis of multiple genes simultaneously. This test falls under the category of Neurological Disorders.
Doctor and Test Department
The TTBK2 Gene Spinocerebellar Ataxia Type 11 autosomal dominant genetic test is conducted by a Neurologist in the Genetics department.
Pre Test Information
Before undergoing the TTBK2 Gene Spinocerebellar Ataxia Type 11 autosomal dominant genetic test, it is important to provide the clinical history of the patient. Additionally, a Genetic Counselling session will be conducted to draw a pedigree chart of family members affected by SCA11.
Test Details
The TTBK2 gene is associated with Spinocerebellar Ataxia Type 11 (SCA11). This genetic disorder is characterized by progressive ataxia and other neurological symptoms. The NGS technology is used to sequence the TTBK2 gene and identify any disease-causing mutations or variations. A DNA sample is obtained from the individual, typically through blood or saliva. The DNA is then sequenced using NGS technology, and the resulting data is analyzed for variations or mutations in the TTBK2 gene. If a disease-causing mutation or variation is found, it confirms a diagnosis of SCA11. The test can also identify individuals at risk of developing the condition, allowing for early intervention and management strategies. It is crucial to consult a healthcare professional or genetic counselor for proper interpretation of the test results and appropriate counseling and support.
| Test Name | TTBK2 Gene Spinocerebellar ataxia type 11 autosomal dominant Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card o |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Neurological Disorders |
| Doctor | Neurologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for TTBK2 Gene Spinocerebellar ataxia type 11, autosomal dominant NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with TTBK2 Gene Spinocerebellar ataxia type 11, autosomal dominant |
| Test Details |
The TTBK2 gene is associated with Spinocerebellar Ataxia Type 11 (SCA11), which is an autosomal dominant genetic disorder characterized by progressive ataxia (lack of muscle coordination) and other neurological symptoms. Next-generation sequencing (NGS) is a high-throughput DNA sequencing technology that can be used to analyze multiple genes simultaneously. In the context of genetic testing for SCA11, NGS can be used to sequence the TTBK2 gene to identify any disease-causing mutations or variations. An NGS genetic test for SCA11 would involve obtaining a DNA sample from the individual undergoing testing, typically through a blood or saliva sample. The DNA is then sequenced using NGS technology, and the resulting sequence data is analyzed to identify any variations or mutations in the TTBK2 gene. If a disease-causing mutation or variation is identified in the TTBK2 gene, it can confirm a diagnosis of SCA11 in the individual being tested. Additionally, genetic testing can also be used to identify individuals who are at risk of developing the condition, allowing for early intervention and management strategies. It’s important to note that genetic testing for SCA11 should be done under the guidance of a healthcare professional or genetic counselor who can help interpret the results and provide appropriate counseling and support. |
